605 related articles for article (PubMed ID: 17621865)
1. Emerging bone health issues in women with breast cancer in Hawai'i.
Carney JF; Davis J
Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
[TBL] [Abstract][Full Text] [Related]
2. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
3. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
4. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
[TBL] [Abstract][Full Text] [Related]
5. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
6. Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer.
Vestergaard P; Rejnmark L; Mosekilde L
Calcif Tissue Int; 2008 May; 82(5):334-40. PubMed ID: 18463912
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors and bone health.
Bundred NJ
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
[TBL] [Abstract][Full Text] [Related]
8. Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors.
Clunie GP; Clark A; Mortimer CJ; Stephenson S; Aitken J; Smith C; Sherwin E; Archer TJ
Eur J Surg Oncol; 2009 May; 35(5):475-80. PubMed ID: 18950981
[TBL] [Abstract][Full Text] [Related]
9. Update on aromatase inhibitors in breast cancer.
Gould RE; Garcia AA
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):41-6. PubMed ID: 16493259
[TBL] [Abstract][Full Text] [Related]
10. Prevention of osteoporosis after breast cancer.
Reid DM
Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant aromatase inhibitors and bone health.
Chowdhury S; Pickering LM; Ellis PA
J Br Menopause Soc; 2006 Sep; 12(3):97-103. PubMed ID: 16953982
[TBL] [Abstract][Full Text] [Related]
12. Extended adjuvant endocrine therapy of early breast cancer.
Chowdhury S; Ellis P
Curr Med Res Opin; 2005 Dec; 21(12):1985-95. PubMed ID: 16368050
[TBL] [Abstract][Full Text] [Related]
13. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network.
Aiello EJ; Buist DS; Wagner EH; Tuzzio L; Greene SM; Lamerato LE; Field TS; Herrinton LJ; Haque R; Hart G; Bischoff KJ; Geiger AM
Breast Cancer Res Treat; 2008 Feb; 107(3):397-403. PubMed ID: 17393300
[TBL] [Abstract][Full Text] [Related]
14. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Hadji P; Bundred N
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
[TBL] [Abstract][Full Text] [Related]
15. Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen?
Ding H; Field TS
Cancer Treat Rev; 2007 Oct; 33(6):506-13. PubMed ID: 17573199
[TBL] [Abstract][Full Text] [Related]
16. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
Coleman RE; Body JJ; Gralow JR; Lipton A
Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
[TBL] [Abstract][Full Text] [Related]
17. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
Poole R; Paridaens R
Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
19. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
Litsas G
Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
[TBL] [Abstract][Full Text] [Related]
20. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
Rozenberg S; Carly B; Liebens F; Antoine C
Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
